Patents by Inventor Hideomi KIJIMA

Hideomi KIJIMA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SALT AND CRYSTAL FORM OF COMPOUND HAVING AGONISTIC ACTIVITY TO S1P5 RECEPTOR
    Publication number: 20220289675
    Abstract: An object of the present invention is to provide a compound with an improved balance of S1P5 receptor agonist activity with respect to S1P1 receptor, and a form suitable for drug substances of pharmaceuticals. Provided is Compound I having high S1P5 receptor-selective agonist activity on the S1P1 receptor. In addition, the crystal forms of Compound I, the salts of Compound I, and the crystal forms of salts thereof disclosed in the present invention are provided as drug substances of pharmaceuticals.
    Type: Application
    Filed: August 19, 2020
    Publication date: September 15, 2022
    Applicant: ONO PHARMACEUTICALCO.,LTD.
    Inventors: Shuhei OTANI, Takayuki FUJITO, Naoko IMURA, Hideomi KIJIMA, Stephan D. PARENT, Melanie Janelle BEVILL, Courtney S. JOHNSON, Travis Lee HOUSTON
  • Ethane-sulfonate salt of quinoline derivative
    Patent number: 10836747
    Abstract: The present invention relates to an ethane-sulfonate salt of N-{5-[(6,7-dimethoxy-4-quinolinyl)oxy]-2-pyridinyl}-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydro-3-quinolinecarboxamide, which has an Axl-inhibiting activity and is useful as a prophylactic and/or therapeutic agent for immune diseases, cancer and the like, a crystal thereof, and a pharmaceutical composition thereof.
    Type: Grant
    Filed: January 25, 2018
    Date of Patent: November 17, 2020
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Takahiro Nekado, Hideomi Kijima, Shizuka Ono, Toshihiko Nishiyama
  • ETHANE-SULFONATE SALT OF QUINOLINE DERIVATIVE
    Publication number: 20190389837
    Abstract: The present invention relates to an ethane-sulfonate salt of N-{5-[(6,7-dimethoxy-4-quinolinyl)oxy]-2-pyridinyl}-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydro-3-quinolinecarboxamide, which has an Axl-inhibiting activity and is useful as a prophylactic and/or therapeutic agent for immune diseases, cancer and the like, a crystal thereof, and a pharmaceutical composition thereof.
    Type: Application
    Filed: January 25, 2018
    Publication date: December 26, 2019
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Takahiro NEKADO, Hideomi KIJIMA, Shizuka ONO, Toshihiko NISHIYAMA
  • Acid-addition salt of Trk-inhibiting compound
    Patent number: 10399959
    Abstract: In order to provide a prophylactic and/or therapeutic agent for Trk-related diseases, the present invention provides a compound which has a selective Trk-inhibiting activity and persistently inhibits NGF vascular hyper permeability and does not have a drug interaction and in addition thereto, is excellent in solubility and absorbability against free bases. The compound of the present invention has a selective Trk-inhibiting activity and persistently inhibits NGF vascular hyper permeability and does not have a drug interaction and is excellent in solubility and absorbability against free bases, and is therefore useful as a prophylactic and/or therapeutic agent for Trk-related diseases.
    Type: Grant
    Filed: August 17, 2015
    Date of Patent: September 3, 2019
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Jun Takeuchi, Satoshi Itadani, Masahiro Ikura, Masato Higashino, Hideomi Kijima, Shizuka Ono, Tetsuya Yasuhiro, Takeshi Nagaura
  • CRYSTAL POLYMORPHISM OF KCNQ2-5 CHANNEL ACTIVATOR
    Publication number: 20190135755
    Abstract: Crystal polymorphism may exist in a crystalline compound. In the case where crystal polymorphism exists, depending on the crystal form, solubility, dissolution rate, stability against heat, light, humidity, etc. or the like is different. Accordingly, in the production of a pharmaceutical product, it is a very important task to select a crystal form of a drug substance most suitable for a disease indication and a dosage form. The present invention relates to novel crystal forms (A crystal, W crystal, and a hydrate crystal (H crystal)) of a compound I having a strong opening action with respect to KCNQ2-5 channels.
    Type: Application
    Filed: April 21, 2017
    Publication date: May 9, 2019
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Kentaro YASHIRO, Hideomi KIJIMA, Daisuke WAKAMATSU, Tetsuji SAITO
  • ACID-ADDITION SALT OF Trk-INHIBITING COMPOUND
    Publication number: 20170240527
    Abstract: In order to provide a prophylactic and/or therapeutic agent for Trk-related diseases, the present invention provides a compound which has a selective Trk-inhibiting activity and persistently inhibits NGF vascular hyper permeability and does not have a drug interaction and in addition thereto, is excellent in solubility and absorbability against free bases. The compound of the present invention has a selective Trk-inhibiting activity and persistently inhibits NGF vascular hyper permeability and does not have a drug interaction and is excellent in solubility and absorbability against free bases, and is therefore useful as a prophylactic and/or therapeutic agent for Trk-related diseases.
    Type: Application
    Filed: August 17, 2015
    Publication date: August 24, 2017
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Jun TAKEUCHI, Satoshi ITADANI, Masahiro IKURA, Masato HIGASHINO, Hideomi KIJIMA, Shizuka ONO, Tetsuya YASUHIRO, Takeshi NAGAURA